4X7I

Crystal Structure of BACE with amino thiazine inhibitor LY2886721


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.77 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.173 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A beta Pharmacodynamic Responses in Mice, Dogs, and Humans.

May, P.C.Willis, B.A.Lowe, S.L.Dean, R.A.Monk, S.A.Cocke, P.J.Audia, J.E.Boggs, L.N.Borders, A.R.Brier, R.A.Calligaro, D.O.Day, T.A.Ereshefsky, L.Erickson, J.A.Gevorkyan, H.Gonzales, C.R.James, D.E.Jhee, S.S.Komjathy, S.F.Li, L.Lindstrom, T.D.Mathes, B.M.Martenyi, F.Sheehan, S.M.Stout, S.L.Timm, D.E.Vaught, G.M.Watson, B.M.Winneroski, L.L.Yang, Z.Mergott, D.J.

(2015) J.Neurosci. 35: 1199-1210

  • DOI: 10.1523/JNEUROSCI.4129-14.2015

  • PubMed Abstract: 
  • BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focus ...

    BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry. Herein, we report the nonclinical and early clinical development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clinical trials in AD. LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclinical animal models. Similar potent and persistent amyloid β lowering was observed in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects. Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.


    Organizational Affiliation

    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Beta-secretase 1
A, B
442Homo sapiensMutation(s): 0 
Gene Names: BACE1 (BACE, KIAA1149)
EC: 3.4.23.46
Find proteins for P56817 (Homo sapiens)
Go to Gene View: BACE1
Go to UniProtKB:  P56817
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
GOL
Query on GOL

Download SDF File 
Download CCD File 
A, B
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
3YS
Query on 3YS

Download SDF File 
Download CCD File 
A, B
N-{3-[(4aS,7aS)-2-amino-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide
C18 H16 F2 N4 O2 S
NIDRNVHMMDAAIK-YPMLDQLKSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
3YSIC50: 20 nM (100) BINDINGDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.77 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.173 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 86.432α = 90.00
b = 89.773β = 90.00
c = 130.663γ = 90.00
Software Package:
Software NamePurpose
REFMACrefinement
SCALAdata scaling
REFMACphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2014-12-09 
  • Released Date: 2014-12-24 
  • Deposition Author(s): Timm, D.E.

Revision History 

  • Version 1.0: 2014-12-24
    Type: Initial release
  • Version 1.1: 2015-02-04
    Type: Database references
  • Version 1.2: 2017-11-22
    Type: Derived calculations, Refinement description, Source and taxonomy